Sugi Predict

Sugi Predict / Compounds / Toluene

Toluene

Toluene

SCHEMBL249116

CC(=O)Cc1ccc(C)cc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ CTBP2 P56545 1/20 0.52
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ CNR1 P21554 1/20 0.49
▸ CNR2 P34972 1/20 0.49
▸ LMNA P02545 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ CES2 O00748 2/20 0.47
▸ CES1 P23141 2/20 0.47
▸ AKR1B1 P15121 1/20 0.46
▸ PSMB8 P28062 1/20 0.46
▸ PSMB5 P28074 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL1076401 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL9462510 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL6422812 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL9293975 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL249639 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL2053140 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL249049 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL1118344 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL3869236 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL1143384 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3362089-B1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS SANOFI PASTEUR (FR) 2023-12-06 — — EP disclosed
CN-108367062-B Immunogenic compositions against staphylococcus aureus 赛诺菲巴斯德有限公司 2022-05-06 — — CN disclosed
US-10772946-B2 Immunogenic compositions against S. aureus SANOFI PASTEUR (FR) 2020-09-15 — — US disclosed
US-20180280491-A1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS SANOFI PASTEUR (FR) 2018-10-04 — — US disclosed
EP-3362089-A1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS Sanofi Pasteur (FR) 2018-08-22 — — EP disclosed
CN-108367062-A Immunogenic compositions against Staphylococcus aureus 赛诺菲巴斯德有限公司 2018-08-03 — — CN disclosed
WO-2017064190-A1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS SANOFI PASTEUR (FR) 2017-04-20 — — WO disclosed
CN-104272148-B The manufacture method of phase retardation film, polaroid and liquid crystal indicator 柯尼卡美能达株式会社 2016-08-31 — — CN disclosed
CN-104272148-A Method for producing phase difference film, polarizing plate, and liquid crystal display device KONICA MINOLTA INC 2015-01-07 — — CN disclosed
EP-2668198-A1 FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-12-04 — — EP disclosed
US-5194602-A 9α-hydroxy-17-methylene steroids, process for their preparation and their use in the preparation of corticosteroids GIST-BROCADES N.V. (NL) 1993-03-16 — — US disclosed
EP-0263569-B1 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives. ROUSSEL-UCLAF (FR) 1992-12-09 — — EP disclosed
EP-0336521-B1 9-ALPHA-HYDROXY-17-METHYLENE STEROIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF CORTICOSTEROIDS ROUSSEL-UCLAF (FR) 1992-04-01 — — EP disclosed
US-5091370-A Antibiotics SANRAKU INCORPORATED (JP) 1992-02-25 — — US disclosed
EP-0404104-A2 Angolamycin derivatives MERCIAN CORPORATION (JP) 1990-12-27 — — EP disclosed
CN-1036774-A 9 alpha-hydroxy-17-methylene steroids, their preparation and their use in the preparation of corticosteroids GIST BROCADES NV (NL) 1989-11-01 — — CN disclosed
WO-1989009781-A1 9-ALPHA-HYDROXY-17-METHYLENE STEROIDS, THEIR PREPARATION AND UTILIZATION GIST-BROCADES N.V. (NL) 1989-10-19 — — WO disclosed
EP-0336521-A1 9-Alpha-hydroxy-17-methylene steroids, process for their preparation and their use in the preparation of corticosteroids ROUSSEL-UCLAF (FR) 1989-10-11 — — EP disclosed
CN-87106868-A 9-alpha-hydroxy steroids, process for their preparation, corresponding 9(11) -dehydro derivatives and pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1988-04-27 — — CN disclosed
EP-0263569-A2 9-alpha-hydroxysteroids, process for their preparation and process for the preparation of the corresponding 9(11)-dehydro-derivatives. ROUSSEL-UCLAF (FR) 1988-04-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180280491-A1 IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS CD4, CSGALNACT1, B3GNT2 L3MBTL1 1884/4885TDP1 4612/4885SMN1; SMN2 4716/4885
US-10772946-B2 Immunogenic compositions against S. aureus CD4, CSGALNACT1, B3GNT2 L3MBTL1 1884/4885TDP1 4612/4885SMN1; SMN2 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.